// App-Quantinova.ai

e20522 : Safety and efficacy of buparlisib (BKM120) and chemotherapy in advanced, squamous non-small cell lung cancer (sqNSCLC): Results from the phase Ib/II BASALT-2 and BASALT-3 studies.

Researchers

Presenter

  • Alex A. Adjei

Principal Investigators

  • Natasha B. Leighl

  • Enriqueta Felip

  • Diego Luigi Cortinovis

  • Juergen Alt

  • Eric Scott Schaefer

  • Michael Thomas

  • Christos Chouaid

  • Alessandro Morabito

  • Javier De Castro

  • Francesco Grossi

  • Luis Paz-Ares

  • Tommaso Martino De Pas

  • Joan Maier

  • Arunava Chakravartty

  • Marie Chol

  • Paola Aimone

  • David Planchard

Medical Centers

  • Roswell Park Cancer Institute, Buffalo, NY

  • Institut de Cancerologie de l'Ouestsite Rene Gauducheau, Saint Herblain, France

  • Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, ON, Canada

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Azienda Ospedaliera San Gerardo, Monza, Italy

  • Universitatsmedizin der Johannes Gutenberg-Universitat Mainz, Mainz, Germany

  • Highlands Oncology Group, Fayetteville, AR

  • Thoraxklinik am Universitatsklinikum Heidelberg, German Center for Lung Research (DZL), Heidelberg, Germany

  • Centre Hospitalier Intercommunal (CHI) Creteil, Creteil, France

  • Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G. Pascale- IRCCS, Naples, Italy

  • Medical Oncology Department and Experimental Therapies and Biomarkers in Cancer, Hospital Universitario La Paz, IDIPAZ, Madrid, Spain

  • AOU San Martino IST, Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • European Institute of Oncology, Milan, Italy

  • Novartis AG, Basel, Switzerland

  • Novartis Healthcare Pvt. Ltd, Hyderabad, India

  • Gustave Roussy Cancer Campus, Villejuif, France

Locations

  • Canada

  • Italy

  • Spain

  • Germany

  • Switzerland

  • United States

  • France

  • India

Companies

  • Novartis AG

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non Small Cell Lung cancer

Biomarkers

  • CREB-binding protein

Drug/Treatment

  • Carboplatin

  • buparlisib

  • Paclitaxel

  • Docetaxel

  • BKM-120

Outcome

  • N/A

Study Design

  • Adaptive

  • Dose Escalation

Phase

  • I

Study Id's

  • NCT01820325

  • NCT01911325

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved